Literature DB >> 11315061

A multivariate test of interaction for use in clinical trials.

D A Follmann1, M A Proschan.   

Abstract

An important issue in clinical trials is whether the effect of treatment is essentially homogeneous as a function of baseline covariates. Covariates that have the potential for an interaction with treatment may be suspected on the basis of treatment mechanism or may be known risk factors, as it is often thought that the sickest patients may benefit most from treatment. If disease severity is more accurately determined by a collection of baseline covariates rather than a single risk factor, methods that examine each covariate in turn for interaction may be inadequate. We propose a procedure whereby treatment interaction is examined along a single severity index that is a linear combination of baseline covariates. Formally, we derive a likelihood ratio test based on the null beta0 = beta1 versus the alternative abeta0 = beta1, where X'beta(k) (k = 0, 1) corresponds to the severity index in arm k and X is a vector of baseline covariates. While our explicit test requires a Gaussian response, it can be readily implemented whenever the estimates of beta0,beta1 are approximately multivariate normal. For example, it is appropriate for large clinical trials where beta(k) is based on a logisitic or Cox regression of response on X.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11315061     DOI: 10.1111/j.0006-341x.1999.01151.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  9 in total

1.  Detecting moderator effects using subgroup analyses.

Authors:  Rui Wang; James H Ware
Journal:  Prev Sci       Date:  2013-04

2.  Generated effect modifiers (GEM's) in randomized clinical trials.

Authors:  Eva Petkova; Thaddeus Tarpey; Zhe Su; R Todd Ogden
Journal:  Biostatistics       Date:  2016-07-27       Impact factor: 5.899

3.  Evaluation of biomarkers for treatment selection using individual participant data from multiple clinical trials.

Authors:  Chaeryon Kang; Holly Janes; Parvin Tajik; Henk Groen; Ben Mol; Corine Koopmans; Kim Broekhuijsen; Eva Zwertbroek; Maria van Pampus; Maureen Franssen
Journal:  Stat Med       Date:  2018-02-14       Impact factor: 2.373

4.  Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence.

Authors:  Issa J Dahabreh; Rodney Hayward; David M Kent
Journal:  Int J Epidemiol       Date:  2016-12-01       Impact factor: 7.196

5.  Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials.

Authors:  James F Burke; Rodney A Hayward; Jason P Nelson; David M Kent
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-01-14

6.  The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration.

Authors:  David M Kent; David van Klaveren; Jessica K Paulus; Ralph D'Agostino; Steve Goodman; Rodney Hayward; John P A Ioannidis; Bray Patrick-Lake; Sally Morton; Michael Pencina; Gowri Raman; Joseph S Ross; Harry P Selker; Ravi Varadhan; Andrew Vickers; John B Wong; Ewout W Steyerberg
Journal:  Ann Intern Med       Date:  2019-11-12       Impact factor: 25.391

7.  Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal.

Authors:  David M Kent; Peter M Rothwell; John P A Ioannidis; Doug G Altman; Rodney A Hayward
Journal:  Trials       Date:  2010-08-12       Impact factor: 2.279

8.  Preventing asthma in high risk kids (PARK) with omalizumab: Design, rationale, methods, lessons learned and adaptation.

Authors:  Wanda Phipatanakul; David T Mauger; Theresa W Guilbert; Leonard B Bacharier; Sandy Durrani; Daniel J Jackson; Fernando D Martinez; Anne M Fitzpatrick; Amparito Cunningham; Susan Kunselman; Lisa M Wheatley; Cindy Bauer; Carla M Davis; Bob Geng; Kirsten M Kloepfer; Craig Lapin; Andrew H Liu; Jacqueline A Pongracic; Stephen J Teach; James Chmiel; Jonathan M Gaffin; Matthew Greenhawt; Meera R Gupta; Peggy S Lai; Robert F Lemanske; Wayne J Morgan; William J Sheehan; Jeffrey Stokes; Peter S Thorne; Hans C Oettgen; Elliot Israel
Journal:  Contemp Clin Trials       Date:  2020-11-24       Impact factor: 2.261

Review 9.  Predictive approaches to heterogeneous treatment effects: a scoping review.

Authors:  Alexandros Rekkas; Jessica K Paulus; Gowri Raman; John B Wong; Ewout W Steyerberg; Peter R Rijnbeek; David M Kent; David van Klaveren
Journal:  BMC Med Res Methodol       Date:  2020-10-23       Impact factor: 4.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.